Recipharm launches serialisation showcase line. 7-Oct-2016 . Packaging | Regulatory. Recipharm’s new line is the latest step in a €40 million project to implement a state-of-the-art solution for its customers’ serialisation requirements across its 75 production lines in Europe

Recipharm equips a further three facilities for US serialisation. 27-Nov-2017 . Contract Manufacturing. Recipharm, a contract development and manufacturing organisation (CDMO) has equipped three more of its facilities with serialisation capabilities, in line with the US regulatory requirements in time for the introduction of the Drug Supply Chain Security Act (DSCSA), 27 November 2017

The facility in Lisbon is the latest of Recipharm’s facilities to be prepared to start supplying serialised products to the US and Europe, following a EUR 40 million investment into its company-wide implementation programme in 2016. Recipharm’s serialisation programme was recently recognised in the TRACKTS Awards 2017 as an example of best practice for its execution of a track and trace system at the Lisbon facility following a detailed assessment of the project’s methodology, use of technology and innovation. Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped three more of its facilities with serialisation capabilities in line with the US regulatory requirements in time for today’s introduction of the Drug Supply Chain Security Act (DSCSA). Recipharm, a leading contract development and manufacturing organisation (CDMO), has released its first serialised products to Europe from its facilities in Lisbon, Portugal and S Recipharm’s three-year serialisation programme began in January 2016 and involves a 40-million-euro investment. Staffan added: “This project milestone reaffirms Recipharm’s global leadership in serialisation and our commitment to meeting the compliance requirements well ahead of the February 2019 deadline.

Recipharm was established in Sweden in 1995 and has since grown to Recipharm takes the lead in serialisation challenge wi. Jan 31, 2017 Staffan Widengren is director of corporate projects at Recipharm and program manager for the Recipharm global serialization project. He has Why serialization? Compliance: Changes in regulations by leading bodies such as US Food and Drug Administration (USFDA) and the European Medicines Mar 27, 2018 Expansion increases the facility's manufacturing capacity by 200 million unidoses /year. Recipharm's new blow-fill-seal machinery is now Dec 28, 2016 The DQSA mandates that all prescription drugs sold in the U.S. must be serialized at both the salable unit level and the case level by November Pharma Serialization is assigning a unique code to the packaging of each drug and printing this code on the packaging by any method.

The challenge of meeting global serialisation requirements can be time consuming and complex.

Jul 13, 2020 Staffan Widengren, Recipharm, and Dexter Tjoa, Tjoapack, describe the The serialization of a product is a complex process that requires the

Recipharm serves more than 250 customers and expects 85% of its production to require serialisation. Kjell Johansson, President Manufacturing Services Europe, added: 'Those companies who fail to prepare for the new regulations will face major disruption to their product supply. As a leading Contract Development and Manufacturing Organisation, Stockholm-headquartered Recipharm has had to grapple with the demands of serialisation both in terms of its internal needs and those of its customers and their supply chains. Erik Haeffler, VP of manufacturing services and head of CSR, shares Recipharm’s experience.

Feb 17, 2016 Recipharm plans to invest €40 million in the project as a result of EMA decision to make serialization of licensed drug products a legal

Recipharm is a CDMO with serialisation firmly on our agenda.

This will help the fight against counterfeit products entering the supply chain and ultimately improve patient safety. Recipharm AB (publ) Recipharm’s three-year serialisation programme began in January 2016 and involves a 40-million-euro investment. Staffan added: “This project milestone reaffirms Recipharm’s global leadership in serialisation and our commitment to meeting the compliance requirements well ahead of the February 2019 deadline. Recipharm has equipped its sixth facility with serialisation capabilities before the US and European regulation enforcement deadlines.
Propionic acid

The announcement marks the next step in the global CDMO’s plans to invest €40m over the next three years to ensure state-of-the-art solutions for serialisation processes.

Recipharm unveils serialisation pricing model Tue, May 24, 2016 09:00 CET. Contract development and manufacturing organisation (CDMO) Recipharm has unveiled plans to improve the affordability of serialisation, with the introduction of a novel pricing model aimed at keeping investment costs down for clients. Recipharm launches serialisation showcase line.
Budget mat recept

Recipharm, ett ledande CDMO-företag (Contract Development and Manufacturing finns på www.recipharm.com/manufacturing/serialisation.

Recipharm announces global serialisation collaboration 23-Jun-2016 . Regulatory. The contract development and manufacturing organisation (CDMO) has formed a global partnership with Marchesini, SEA Vision and TraceLink to introduce new serialisation capabilities Recipharm announces all its facilities are ready for EU serialisation Thu, Feb 14, 2019 10:00 CET During the period 2016-2018, the CDMO invested EUR 35 million into its operations and launched a three-year programme to provide a compliant serialisation solution for its customers, ahead of the introduction of the EU Falsified Medicines Directive (EU FMD) and the US Drug Supply Chain Security Act (DSCSA). Recipharm unveils serialisation pricing model Tue, May 24, 2016 09:00 CET. Contract development and manufacturing organisation (CDMO) Recipharm has unveiled plans to improve the affordability of serialisation, with the introduction of a novel pricing model aimed at keeping investment costs down for clients.